Thyroid cancer linked to in-utero exposures, study shows

A recent study by prof. Tone Bjørge, University of Bergen, and her team shows that thyroid cancer is related to in-utero exposures.

Thyroid cancer is diagnosed at a younger age than most other malignancies and the incidence is higher in women than men.

The only established modifiable risk factors for thyroid cancer are childhood exposure to ionizing radiation and obesity. Few in-utero and early life risk factors have so far been identified."

Bjørge, Professor, Department of Global Public Health and Primary Care, University of Bergen

Maternal hypothyroidism, hyperthyroidism, goiter, and benign thyroid neoplasms related to higher risk

The team conducted a nested case-control study using nationwide registry data from four Nordic countries (Denmark, Finland, Norway, and Sweden). The study included 2,437 thyroid cancer cases and 24,362 matched controls aged 0-48 years during 1967-2015.

"Maternal benign thyroid conditions such as hypothyroidism, hyperthyroidism, goiter, and benign thyroid neoplasms were strongly associated with thyroid cancer risk in offspring. Also, high birth weight, congenital hypothyroidism, maternal history of diabetes, and maternal postpartum hemorrhage were associated with increased risk", says Bjørge.

Motivates further research

The study supports a link between in-utero exposures and an increased risk of thyroid cancer later in life.

"These findings should motivate additional research into early-life exposures that might cause thyroid cancer", says Bjørge.

Source:
Journal reference:

Kitahara, C.M., et al. (2020) Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study. The Lancet. doi.org/10.1016/S2213-8587(20)30399-5.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
New study shows bivalent COVID-19 booster increases antibody response in lung cancer patients